Tech Transfer eNews Blog
University-Industry Engagement Advisor

U of Manchester scores funding round for its minimally invasive back pain treatment

By Jesse Schwartz
Published: November 14th, 2018

A University of Manchester start-up has landed a £1.2 million investment (over $1.55M US) to commercialize a novel, non-surgical solution for lower back pain.

Gelmetix has developed an injectable microgel that can be delivered through a minimally invasive procedure into the gaps left by degenerating discs to help restore functionality and relieve pain. The gel could serve as a more cost-effective and less invasive alternative to surgery for patients with lower back pain.

“Gelmetix is pursuing such as huge and poorly served market in chronic lower back pain,” says angel investor Jonathan Milner, who led the recent funding round through the crowdfunding platform SyndicateRoom.

“It is the single leading cause of disability worldwide and results in a significant financial burden on all developed economies,” adds Milner. “Currently, no minimally invasive solution exists that re-establishes mobility on the continuum between early and late stages of the disease. This is where Gelmetix, with its differentiated technology and a fantastic team, aim to make an impact in human health.”

According to Gelmetix CEO, Dr. Phillipe Jenny, the start-up aims to use the funds to further develop its product for commercialization and support the preclinical work for two additional get products.

Tom Britton, co-founder of SyndicateRoom, comments, “It’s incredible to think that with all of the advancements in technology and medicine over the last 100 years, we’ve not found better ways of treating back pain, which so many of us accept as the norm. Gelmetix’s solution offers hope that a less risky, less invasive solution is possible, and we are delighted our investors and fund are able to play a part in their journey.”

Source: Manchester Evening News

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment